Foghorn Therapeutics Inc.FHTXNASDAQ
Loading
FHTX Revenue Growth (YoY Quarterly)•+223.77%
Stock Alarm Pro
Growth Metrics
Latest: Q4 2025vs Q3 2025
Revenue GrowthGross Profit GrowthEBITDA GrowthOperating Income GrowthNet Income GrowthEPS GrowthEPS Diluted GrowthWeighted Average Shares GrowthWeighted Average Shares Diluted GrowthDividends per Share Growth
+223.77%
+219.4pp
+195.69%
+447.4pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.60%
-0.1pp
+0.60%
-0.1pp
+0.00%
+0.0pp
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -50.49% | +17.86% | +9.71% | +4.42% | +223.77% |
| Gross Profit Growth | -41.92% | +17.86% | -3.35% | -251.75% | +195.69% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +48.06% | +48.13% | +22.10% | +0.68% | +0.60% |
| Weighted Average Shares Diluted Growth | +48.06% | +48.13% | +22.10% | +0.68% | +0.60% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -0.68% | +1.45% | -31.15% | -33.53% | -30.24% |
| Book Value per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Debt Growth | -17.62% | -18.91% | -42.08% | -42.34% | +11.15% |
| R&D Expense Growth | -12.18% | -15.31% | -12.21% | -18.98% | +11.89% |
| SG&A Expenses Growth | -9.53% | -6.11% | -6.32% | -4.58% | +6.99% |
1 / 4